Allergan Settles DOJ Botox Probe for $600 million
Written By: Rheingold, Giuffra, Ruffo & Plotkin LLP
Allergan has plead guilty to one misdemeanor in connection with off-label marketing of Botox and agreed to pay $600 million in fines, civil penalties, and to cover civil claims asserted under the False Claims Act.
Sally Yates, US Attorney for the North District of Georgia said, "The FDA had approved therapeutic uses of Botox for only four rare conditions, yet Allergan made it a top corporate priority to maximize sales of far more lucrative off-label uses that were not approved by the FDA."
Allergan also agreed to dismiss their First Amendment lawsuit in which they sought to win the right to distribute information about upapproved uses for Botox.
If you have been injured as a result of the harmful side effects of a drug contact the attorneys at Rheingold, Giuffra, Ruffo & Plotkin LLP to speak with an experienced New York product liability lawyer.